| Name | Title | Contact Details |
|---|
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.
DiNovo is a distributor of USP <797> <71> <800> compliance products, packaging solutions, and infusion supplies. We are designed to bring innovative products at a low cost to the healthcare market place.
Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.
Solutions for isolation, recovery, and analysis of intact, individual rare cells. Single "cell sorter"
Tibotec (tee-bo-tek) Therapeutics was established in March 2003 as a division of Ortho Biotech Products, L.P. Headquartered in Bridgewater, N.J., the organization is dedicated to providing innovative virology therapeutics that help healthcare